Alpha Tau: Head and Neck Data Continues to Support Alpha DaRT's Tumor Agnostic Value Proposition

Research evidence excerpt

Alpha Tau: Head and Neck Data Continues to Support Alpha DaRT's Tumor Agnostic Value Proposition

Equity Research

U.S. Small & Mid Cap Biotechnology

21 July 2026

Alpha Tau

Head and Neck Data Continues to

Support Alpha DaRT's Tumor First Look

DRTS OVERWEIGHTAgnostic Value Proposition

U.S. Small & Mid Cap POSITIVE

HNSCC data further strengthens Alpha DaRT's differentiated Biotechnology Price Target USD 17.00

approach and potentially tumor agnostic application. Price (20-Jul-26) USD 13.47

Durability is a question, but safety profile supports Potential Upside/Downside +26.2% Source: Bloomberg, Barclays Research

combination approaches.

DRTS announced updated data from the clinical study evaluating Alpha DaRT radioactive Lukas Shumway, PhD

implants in combination with pembrolizumab in elderly patients in Israel with previously +1 212 526 7293

untreated head and neck cancer (1L HNSCC) via press release. The data will be presented today lukas.shumway@barclays.com

BCI, USat the American Head and Neck Society (AHNS) meeting in Bostons in a podium session. In 9

response-evaluable patients, the combination achieved a 100% response rate, with 4 complete Etzer Darout, PhD, MBA

responses (CR) and 5 partial responses (PR). Median PFS was 5.4 months and OS was 18.2 +1 212 526 6940

months. The data compares favorably to the current 1L HNSCC standard of care of etzer.darout@barclays.com

BCI, USpembrolizumab across all three efficacy outcomes, but we'd need to see more data in more

patients for comparisons with clinical contemporaries, including the petosemtamab plus

pembrolizumab combination being evaluated by GMAB (covered by James Gordon) in the

ongoing Phase 3 LiGeR-HN1 trial. Alpha DaRT treatment led to only two adverse events related

to treatment, and both were Grade 1.